VIRMA and hepatocellular carcinoma: To confirm whether GATA3 was a dominant contributor to the malignant cell phenotypes promoted by KIAA1429 or GATA3-AS, we evaluated whether GATA3 inhibition could rescue the effects of KIAA1429 or GATA3-AS knockdown on the biological behaviors of hepatoma cells.